


PHARMACEUTICAL 2022

Indaptus Therapeutics Inc. Rank 112 of 475





PHARMACEUTICAL 2022



Indaptus Therapeutics Inc. Rank 112 of 475

The relative strengths and weaknesses of Indaptus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Indaptus Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 212% points. The greatest weakness of Indaptus Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 313% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	40,387
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,604
Liabilities, Non-Current	73
Other Assets	186
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	18
Property and Equipment	3.8
Research and Development	2,523
Revenues	0
Selling, General and Administrative Expense	5,206

Output Variable	Value in 1000 USD
Assets	40,577
Liabilities	4,677
Expenses	7,729
Stockholders Equity	35,900
Net Income	-7,711
Comprehensive Net Income	-7,711
Economic Capital Ratio	36%